These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39192804)

  • 1. Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants.
    Hung HC; Tan BF; Lin WS; Wu SC
    J Med Virol; 2024 Sep; 96(9):e29893. PubMed ID: 39192804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
    Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
    Front Immunol; 2021; 12():795741. PubMed ID: 34925381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L
    J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    Fryer HA; Geers D; Gommers L; Zaeck LM; Tan NH; Jones-Freeman B; Goorhuis A; Postma DF; Visser LG; Hogarth PM; Koopmans MPG; GeurtsvanKessel CH; O'Hehir RE; van der Kuy PHM; de Vries RD; van Zelm MC
    J Infect; 2024 Oct; 89(4):106246. PubMed ID: 39127451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses.
    Liang Z; Li C; Gong X; Ye G; Jiang Y; Shi H; Hussain A; Zhao M; Li M; Tian Y; Zhao W; Yang Y; Huang Y; Shen C; Yang M
    PLoS Pathog; 2024 Sep; 20(9):e1012599. PubMed ID: 39325829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
    Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ
    Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.
    Cao Y; Jian F; Wang J; Yu Y; Song W; Yisimayi A; Wang J; An R; Chen X; Zhang N; Wang Y; Wang P; Zhao L; Sun H; Yu L; Yang S; Niu X; Xiao T; Gu Q; Shao F; Hao X; Xu Y; Jin R; Shen Z; Wang Y; Xie XS
    Nature; 2023 Feb; 614(7948):521-529. PubMed ID: 36535326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
    Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F
    BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants.
    Luo M; Zhou R; Tang B; Liu H; Chen B; Liu N; Mo Y; Zhang P; Lee YL; Ip JD; Wing-Ho Chu A; Chan WM; Man HO; Chen Y; To KK; Yuen KY; Dang S; Chen Z
    EBioMedicine; 2024 Oct; 108():105354. PubMed ID: 39341153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.
    Chang TY; Li CJ; Chao TL; Chang SY; Chang SC
    Appl Microbiol Biotechnol; 2024 Oct; 108(1):486. PubMed ID: 39412657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
    Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
    Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
    Yang S; Yu Y; Jian F; Yisimayi A; Song W; Liu J; Wang P; Xu Y; Wang J; Niu X; Yu L; Wang Y; Shao F; Jin R; Wang Y; Cao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2343909. PubMed ID: 38616729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.